PHILADELPHIA, Jan. 7 /PRNewswire/ -- ERT, a leading provider of centralized services to the biopharmaceutical, medical device and related industries, announced the appointment of John Sory to the newly created role of Senior Vice President of Health Care Solutions. This strategic appointment will enable ERT to leverage its core expertise into the larger health care market. Mr. Sory will be responsible for developing this growth area as well as exploring merger and acquisition opportunities in clinical research. He will report to the President and CEO of ERT, Dr. Michael McKelvey.
The health care industry increasingly requires technical connectivity across the health system, remote clinical review and data services to augment and support the process of care delivery and robust analytics to evaluate the improvement in patient health. ERT is highly experienced in developing similar comprehensive, efficient, centralized solutions for the clinical trials industry. This new appointment demonstrates the Company's desire to leverage and expand its established expertise and core capabilities, with the ultimate goal of building diversified revenue streams to complement our clinical trial business.
Mr. Sory joins ERT following 16 years of experience working for Pfizer, Inc. He spent the last seven years as Vice President and General Manager of Pfizer Health Solutions, Inc, Pfizer's health technology and services subsidiary. John brings extensive business development experience working on partnerships, joint ventures, and mergers, as well as operations experience having managed innovative health care initiatives in the U.S. and Europe. A high level industry executive, Mr. Sory has demonstrated his ability to successfully leverage a company's resources, talent and intellectual property across many divergent sectors of the health care system.
Dr. Michael McKelvey, President and CEO of ERT, comments, "With his wealth of new business development and managerial experience and capabilities, we are confident that John will establish ERT's presence in the broader health care market. His appointment marks the next stage of ERT's continued investment to growing our business into adjacent and complementary markets."
John Sory adds, "ERT's industry-leading technology and solutions, which have driven its success in the cardiac safety area of clinical trials, can be leveraged in unique ways for the health care market and in other areas of clinical trials. I am delighted to lead the path toward this goal. In this time of intensive health reform, we have an opportunity to bring established competencies to the market in exciting new ways. We look forward to developing our strategy, that will allow us to build, partner, pilot and launch a number of meaningful and innovative products and services."
For further press information, please contact Fiona Robinson, The Scott Partnership, 1 Whiteside, Station Road, Holmes Chapel, Cheshire CW4 8AA, United Kingdom. Phone +44 1477 539539, Fax +44 1477 539540, Email email@example.com
Based in Philadelphia, PA ERT (eResearchTechnology, Inc.) (www.ERT.com) is a global provider of technology and services to the biopharmaceutical, medical device, and related industries. The Company is the market leader in providing centralized core-diagnostic electrocardiographic (ECG) technology and services to evaluate cardiac safety in clinical development. The Company also provides technology and services to streamline the clinical trials process by enabling its customers to automate the collection, analysis, and distribution of clinical data in all phases of clinical development.
Statements included in this release may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements involve a number of risks and uncertainties, which could cause actual results to differ materially from those expressed or implied from such statements. These risks and uncertainties include, without limitation, the Company's ability to obtain new contracts, variability in size, scope, and duration of projects, integration of acquisitions, competitive factors, technological development, market demand, and other factors described in the Company's filings with the Securities and Exchange Commission. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise.